This topic contains a solution. Click here to go to the answer

Author Question: Which of the Galilean moons is the densest and most geologically active? A) Io B) Europa C) ... (Read 33 times)

robinn137

  • Hero Member
  • *****
  • Posts: 544
Which of the Galilean moons is the densest and most geologically active?
 
  A) Io
  B) Europa
  C) Ganymede
  D) Callisto
  E) Titan

Question 2

Rhea, Saturn's second largest moon, might best be described as:
 
  A) having a very reflective, icy surface that is heavily cratered.
  B) orbiting in a highly elliptical orbit, far from Saturn.
  C) having the leading hemisphere six times darker than the following one.
  D) being composed of the densest material of any Saturnian moon and dark in appearance.
  E) being the only major moon of any planet not in synchronous rotation.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Moriaki

  • Sr. Member
  • ****
  • Posts: 341
Answer to Question 1

A

Answer to Question 2

A




robinn137

  • Member
  • Posts: 544
Reply 2 on: Jul 27, 2018
YES! Correct, THANKS for helping me on my review


mohan

  • Member
  • Posts: 362
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

For about 100 years, scientists thought that peptic ulcers were caused by stress, spicy food, and alcohol. Later, researchers added stomach acid to the list of causes and began treating ulcers with antacids. Now it is known that peptic ulcers are predominantly caused by Helicobacter pylori, a spiral-shaped bacterium that normally exist in the stomach.

Did you know?

Allergies play a major part in the health of children. The most prevalent childhood allergies are milk, egg, soy, wheat, peanuts, tree nuts, and seafood.

Did you know?

Symptoms of kidney problems include a loss of appetite, back pain (which may be sudden and intense), chills, abdominal pain, fluid retention, nausea, the urge to urinate, vomiting, and fever.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

Women are 50% to 75% more likely than men to experience an adverse drug reaction.

For a complete list of videos, visit our video library